More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$130.58B
EPS
15.53
P/E ratio
29.7
Price to sales
10.27
Dividend yield
--
Beta
0.281262
Previous close
$520.66
Today's open
$529.94
Day's range
$513.80 - $531.37
52 week range
$412.27 - $568.67
show more
CEO
Reshma Kewalramani
Employees
6400
Headquarters
Boston, MA
Exchange
Nasdaq Global Select
Shares outstanding
253537674
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Vertex Pharmaceuticals: Look For Povetacicept Approval In 2 Weeks As Next Catalyst
Vertex Pharmaceuticals Incorporated remains a Buy: shares look fairly valued, but durable CF cash flows and pipeline potential support long-term market outperformance. VRTX's CF franchise accounts for an estimated 60% of market value, with high-single-digit growth and patent protection supporting a decade of cash generation. Journavx offers the strongest approved non-CF opportunity, with growing prescriptions and off-label demand offsetting pricing headwinds and chronic-pain trial risk.
Seeking Alpha • Nov 20, 2026

2 Growth Stocks to Buy in November Without Any Hesitation
Vertex Pharmaceuticals' core business remains healthy, and it has a portfolio of kidney disease candidates that could top $10 billion in annual sales. Regeneron's Dupixent looks unstoppable, while a newer formulation of Eylea cushions the decline of the older version.
The Motley Fool • Nov 19, 2026

Worried investors are paying up for these stocks — some with up to 49% upside, analysts say
Defensive sectors have beaten the S&P 500 by a wide margin in recent months, even though they are priced much higher relative to earnings estimates than the index.
Market Watch • Nov 18, 2026

Vertex Pharmaceuticals Eyes Nov. 30 Kidney Drug Decision as 2027 Pipeline Milestones Loom
Vertex Pharmaceuticals NASDAQ: VRTX is approaching a Nov. 30 U.S. regulatory decision for its kidney disease drug povetacicept, with a series of clinical readouts expected through 2027 as the company seeks to expand beyond its cystic fibrosis business.
MarketBeat • Nov 17, 2026

Vertex Pharmaceuticals Incorporated (VRTX) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Seeking Alpha • Nov 17, 2026

Johnson & Johnson vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?
Johnson & Johnson offers a diversified healthcare portfolio and massive scale across its MedTech and pharmaceutical segments. Vertex Pharmaceuticals maintains a dominant position in the cystic fibrosis market while expanding into high-growth gene therapies.
The Motley Fool • Nov 17, 2026

Vertex Pharmaceuticals Prepares for Key Kidney Drug Decision as Pipeline Readouts Loom
Vertex Pharmaceuticals NASDAQ: VRTX is preparing for a Nov. 30 U.S. regulatory decision on its kidney disease treatment povetacicept, while awaiting clinical results across kidney disease, chronic pain and other conditions, company executives said at a UBS investor event.
MarketBeat • Nov 16, 2026

Vertex Pharmaceuticals Incorporated (VRTX) Presents at UBS Global Biopharma Conference 2026 Transcript
Vertex Pharmaceuticals Incorporated (VRTX) Presents at UBS Global Biopharma Conference 2026 Transcript
Seeking Alpha • Nov 16, 2026

Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?
Amgen maintains a massive global footprint and a highly diversified portfolio of medicines for serious conditions. Vertex Pharmaceuticals dominates the cystic fibrosis market and is expanding into gene editing and pain management.
The Motley Fool • Nov 13, 2026

Impax Small Cap Fund Q3 2026 Portfolio Review
The portfolio outperformed the Russell 2000 Index in what was a difficult period for the small cap asset class. Financials was the largest contributing sector, almost entirely due to stock selection. Top contributors include Victory Capital and Acadian Asset Management.
Seeking Alpha • Nov 12, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Vertex Pharmaceuticals Incorporated commission-free¹. Build wealth for the long term using automated trading and transfers.